title: Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis.
abstract: BACKGROUND
  5-Lipoxygenase products of arachidonic acid metabolism are thought to play a central role in the secondary amplification of the inflammatory response in a number of human inflammatory diseases, such as ulcerative colitis. MK-0591 (3-(1((4-chlorophenyl)methyl)-3((1,1-dimethyl-ethyl)thio)-5(quinolin+ ++-2ylmethyl-oxy)-1H-indol-2yl)-2,2-dimethyl-propanoate) exerts its effect by binding to the 5-lipoxygenase activating protein, thereby inhibiting the translocation and activation of 5-lipoxygenase.
  
  
  METHODS
  Concentrations of leukotriene B4 (LTB4) and prostaglandin E2 (PGE2) in rectal dialysis fluid, ex vivo biosynthesis of LTB4 in whole blood, and urinary excretion of leukotriene E4 (LTE4) from 16 patients with mild to moderately active distally located ulcerative colitis were measured by use of radioimmunoassays in a double-blind, placebo-controlled parallel-design study before and after oral administration of a 250 mg dose of MK-0591 or placebo.
  
  
  RESULTS
  The mean LTB4 concentration in rectal dialysis fluid was lowered after MK-0591 by > 90% (p < 0.05) from 4 to 8 hours, with a maximum inhibition of 97.5% +/- 3.4% (mean +/- SD) at 20 to 24 hours after dosing, whereas PGE2 was unchanged. In whole blood, MK-0591 decreased ex vivo biosynthesis of LTB4 (p < 0.01), with a maximum inhibition of 96.4% +/- 2.1% at 4 hours after dosing. Urinary excretion of LTE4 was reduced by more than 85% (p < 0.001) from 4 to 48 hours. No adverse events were observed.
  
  
  CONCLUSIONS
  These findings show that a single oral 250 mg dose of MK-0591 results in nearly complete blockade of systemic leukotriene production and LTB4 formation in the target tissue of inflammation (the rectum). Controlled multiple-dose trials to assess the clinical efficacy of this novel 5-lipoxygenase-activating protein inhibitor seem to be worthwhile.
authors.affiliation: Department of Medical Gastroenterology, Hvidovre Hospital, Denmark.
authors.forename: J
authors.initials: J
authors.lastname: Hillingsø
authors.forename: J
authors.initials: J
authors.lastname: Kjeldsen
authors.forename: L S
authors.initials: LS
authors.lastname: Laursen
authors.forename: K
authors.initials: K
authors.lastname: Lauritsen
authors.forename: S
authors.initials: S
authors.lastname: von Spreckelsen
authors.forename: M
authors.initials: M
authors.lastname: Depré
authors.forename: B S
authors.initials: BS
authors.lastname: Friedman
authors.forename: K
authors.initials: K
authors.lastname: Malmström
authors.forename: S
authors.initials: S
authors.lastname: Shingo
authors.forename: K
authors.initials: K
authors.lastname: Bukhave
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000328:Adult; D003093:Colitis, Ulcerative / Q000378:metabolism*; D015232:Dinoprostone / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology*; D007975:Leukotriene B4 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis*; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D007211:Indoles; D011804:Quinolines; C078266:MK 0591; D007975:Leukotriene B4; D015232:Dinoprostone